SCHEMBL324010

SCHEMBL324010

c1ccc(Cn2ccc3cccnc32)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.49
CYP2C19 P33261 2/20 0.49
MEN1 O00255 2/20 0.49
KDM4E B2RXH2 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
ATM Q13315 1/20 0.49
MTNR1A P48039 1/20 0.48
P2RX7 Q99572 1/20 0.47
HTR6 P50406 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.45
DAO P14920 1/20 0.45
APP P05067 1/20 0.43
SNCA P37840 1/20 0.43
PARP1 P09874 1/20 0.42
PDE4A P27815 1/20 0.42
LMNA P02545 1/20 0.42
TP53 P04637 1/20 0.41
PABPC1 P11940 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL38652062 1.00 KMT2A (0.49) KMT2ACYP2C19MEN1KDM4ECYP1A2
SCHEMBL15142922 0.87 PKM (0.51) KMT2ACYP2C19MEN1KDM4ECYP1A2
SCHEMBL5194675 0.86 P2RX7 (0.52) KMT2ACYP2C19MEN1KDM4ECYP1A2
SCHEMBL38652446 0.85 MTNR1A (0.45) KMT2ACYP2C19MEN1CYP1A2MTNR1A
SCHEMBL29643774 0.85 PTK2 (0.49) KMT2AKDM4EATMMTNR1ADAO
SCHEMBL9278020 0.85 TP53 (0.45) KMT2ACYP2C19MEN1KDM4ECYP1A2
SCHEMBL38652459 0.85 HTT (0.56) KDM4EMTNR1AHTR6L3MBTL1LMNA
SCHEMBL30167862 0.84 CYP2C19 (0.53) KMT2ACYP2C19MEN1MTNR1AP2RX7
Ethoxycarbonyl Group SCHEMBL27728898 0.84 MTNR1A (0.43) KMT2ACYP2C19MEN1KDM4ECYP1A2
SCHEMBL38652180 0.82 KDM4E (0.56) KMT2ACYP2C19MEN1KDM4ECYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111471044-B Synthesis method of palladium-catalyzed 3-aryl 7-azaindole compound 西北大学 2021-08-10 CN claimed
CN-111471044-A Synthesis method of palladium-catalyzed 3-aryl 7-azaindole compound 西北大学 2020-07-31 CN claimed
US-11753421-B2 Silylated derivatives of aromatic heterocycles CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2023-09-12 US disclosed
US-11753421-B2 Silylated derivatives of aromatic heterocycles CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2023-09-12 US disclosed
US-11753421-B2 Silylated derivatives of aromatic heterocycles CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2023-09-12 US disclosed
CN-111253424-B Silylation of aromatic heterocycles over earth-rich transition metal-free catalysts 加州理工学院 2023-06-20 CN disclosed
EP-3705482-B1 SILYLATION OF AROMATIC HETEROCYCLES BY EARTH ABUNDANT TRANSITION-METAL-FREE CATALYSTS CALIFORNIA INST OF TECHN (US) 2023-02-22 EP disclosed
US-11524966-B1 Carboxamides as ubiquitin-specific protease inhibitors VALO HEALTH, INC. (US) 2022-12-13 US disclosed
US-20220185828-A1 Silylated Derivatives Of Aromatic Heterocycles CALIFORNIA INSTITUTE OF TECHNOLOGY 2022-06-16 US disclosed
US-20220185828-A1 Silylated Derivatives Of Aromatic Heterocycles CALIFORNIA INSTITUTE OF TECHNOLOGY 2022-06-16 US disclosed
US-11312733-B2 Silylated derivatives of aromatic heterocycles CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2022-04-26 US disclosed
CN-1649889-A Process for preparing oligonucleotides AVECIA LTD (GB) 2005-08-03 CN disclosed
EP-1554300-A1 PHOSPHITYLATION PROCESS Avecia Biotechnology, Inc. (US) 2005-07-20 EP disclosed
EP-1501851-A1 PROCESS FOR PREPARING OLIGONUCLEOTIDES Avecia Limited (GB) 2005-02-02 EP disclosed
CN-1549820-A Activators for oligonucleotide synthesis ƽ 2004-11-24 CN disclosed
WO-2004055036-A1 PROCESS FOR THE PREPARATION OF OLIGONUCLEOTIDES AVECIA LIMITED (GB) 2004-07-01 WO disclosed
WO-2004035599-A1 PHOSPHITYLATION PROCESS AVECIA BIOTECHNOLOGY INC. (US) 2004-04-29 WO disclosed
EP-1404696-A1 ACTIVATORS FOR OLIGONUCLEOTIDE SYNTHESIS Avecia Biotechnology, Inc. (US) 2004-04-07 EP disclosed
WO-2003091267-A1 PROCESS FOR PREPARING OLIGONUCLEOTIDES AVECIA LIMITED (GB) 2003-11-06 WO disclosed
WO-2003004512-A1 ACTIVATORS FOR OLIGONUCLEOTIDE SYNTHESIS AVECIA BIOTECHNOLOGY INC. (US) 2003-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11312733-B2 Silylated derivatives of aromatic heterocycles KCNH1, KCNH3, HNRNPH3 KMT2A 654/4885CYP2C19 2437/4885MEN1 3045/4885
US-11524966-B1 Carboxamides as ubiquitin-specific protease inhibitors USP28, USP25, USP24 KMT2A 339/4885CYP2C19 2677/4885MEN1 3554/4885
US-11753421-B2 Silylated derivatives of aromatic heterocycles KCNH1, KCNH3, HNRNPH3 KMT2A 654/4885CYP2C19 2437/4885MEN1 3045/4885
US-20220185828-A1 Silylated Derivatives Of Aromatic Heterocycles KCNH1, KCNH3, HNRNPH3 KMT2A 654/4885CYP2C19 2437/4885MEN1 3045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.